In the pediatric population, MDS is often associated with an underlying genetic predisposition syndrome, accounting for 30% to 45% of pediatric MDS.
2,4-6 These syndromes include the inherited bone marrow failure syndromes (IBMFS) such as Fanconi anemia (FA), dyskeratosis congenita (DKC), and Shwachman-Diamond syndrome (SDS), as well as familial MDS/AML syndromes such as GATA2 haploinsufficiency and familial platelet disorder with associated myeloid malignancy related to RUNX1 mutations/ deletions. In a summary of all IBMFS, Cada et al 7 estimated a 37% risk of clonal and malignant myeloid transformation by the age of 18 in IBMFS, with the highest actuarial risk in patients with FA (75%), followed by DKC (25%), unclassified IBMFS (24%), Kostmann/severe congenital neutropenia (24%), and SDS (20%). Familial platelet disorder with associated myeloid malignancy has also been found to have an increased risk of clonal hematopoietic changes, estimated at 81% by an age of 50 years. 8 Additionally, germline GATA2 mutations are a leading cause of MDS in pediatrics, especially in adolescents with monosomy 7. For the evaluation of MDS, bone marrow aspirates and biopsies are performed to evaluate for morphologic dysplasia. In addition, cytogenetic analyses are usually performed in order to help identify any abnormal clonal population or the presence of a recurring MDS-defining abnormality. 1 At our institution, patients with IBMFS, suspected to have marrow failure syndromes, or with other acquired marrow failures (such as aplastic anemia) who are at an increased risk for developing MDS, are monitored routinely with bone marrow examinations. Historically, these marrows have been sent for flow cytometry, karyotype, and a MDS fluorescence in situ hybridization (FISH) panel for detecting the common MDS abnormalities: deletion 5q/monosomy 5, monosomy 7/ deletion 7q, trisomy 8, and deletion 20q. In the current study, we analyze the results of these ancillary tests to evaluate their utility in this clinical situation.
Materials and Methods
In this retrospective chart review with Seattle Children's Hospital Institutional Review Board approval, we examined the material from 595 bone marrow aspirate/biopsy cases and ancillary tests in 246 patients from January 2000 to June 3, 2016 . These bone marrows were performed for evaluation of MDS. Patient history (bone marrow failure/predisposition syndrome), sex, and age at time of marrow were recorded. MDS and/or myeloid neoplasms with germline predisposition syndromes were classified per the 2016 World Health Organization classifications for myeloid neoplasms. 10 Peripheral blood values for WBC count, platelet count, hemoglobin, mean corpuscular volume (MCV), and absolute neutrophil count (ANC) at the time of the marrow evaluation were scored as low, high, or normal per age-specific ranges and recorded. The percentage of any peripheral blood blasts at this time point was also noted. Patients with a diagnosis of leukemia and patients who were status post bone marrow transplant were excluded from the study.
Flow cytometry results were recorded as normal, mildly abnormal, or definitively abnormal with the specified findings. Flow cytometry for evaluation of MDS was sent to the University of Washington Hematopathology Laboratory for performance and evaluation. This expert group of hematopathologists uses the difference from normal approach based on their vast expertise of normal patterns of myeloid progenitor, granulocyte, and monocyte maturation. These hematopathologists look for aberrant expression of antigens (such as lymphoid antigens), increased or decreased normal antigen intensity, homogeneous antigen expression, and asynchronous expression of two antigens. [11] [12] [13] Usually, the morphologic and cytogenetic findings were not provided with the flow cytometry order, so the hematopathologists were blinded to those findings.
Cytogenetic studies were performed from two unstimulated overnight cultures using standard G-banding techniques with at least 20 metaphase cells analyzed when possible. Karyotype results were recorded as normal or abnormal with the identified karyotype and number of abnormal metaphase cells. The MDS FISH panel included commercially available probes that were hybridized according to manufacturer protocols. For deletion 5q/monosomy 5, probes for EGR1 (5q31.2) and D5S23/D5S721 (5p15.2) from Vysis (Abbott Laboratories, Abbott Park, IL) were employed before August 2011, with cut-off values of 2.2% for del(5q) and 0% for monosomy 5; after August 2011, probes for EGR1 (5q31.2) and D5S630/ D5S2064 (5p15.31) from Cytocell (Tarrytown, NY) were employed with cut-off values of 4.2% for del(5q) and 1.8% for monosomy 5. For deletion 7q/monosomy 7, probes for D7S522 (7q31) and D7Z1 (7 cen) from Vysis were employed before June 2013, with cut-off values of 4.2% for del(7q) and 1.5% for monosomy 7; after July 2013, probes for D7S486 (7q31) and D7Z1 (7 cen) from Vysis were employed with cut-off values of 4.3% for del(7q) and 2.7% for monosomy 7. A probe for D8Z2 (8 cen; Cytocell) was used prior to June 2011 to detect trisomy 8 (cut-off of 3%); after June 2011, a MYC probe (8q24.1; Vysis) was added to decrease the positive cut-off rate to 1.5%. Probes for del(20q) were only employed in the MDS FISH panel after June 2009, in which PTPRT (20q12) and MYBL2 (20q13.2) probes, both from Cytocell, were employed with a cutoff rate of 4.8%. For each probe set, 200 nuclei were scored. 14 The MDS FISH results were recorded as normal or abnormal with the identified abnormalities and percent of cells with abnormalities.
In review of the bone marrow reports, the presence of dysplasia, specific lineage, and increased blasts were noted. As the bone marrow morphologic reviews were performed real time by a variety of pathologists with subjective qualifiers for dysplasia, all bone marrow cases with any degree of dysplasia and/or abnormal ancillary tests were rereviewed by a single hematopathologist (K.M.C.) for quantified degree of dysplasia, less than 10% or equal to or greater than 10%. In this rereview, Wright-stained bone marrow aspirates and H&E-stained core biopsies from 117 cases were evaluated for morphologic features of megakaryocytes, erythroid cells, myeloid cells, and blasts blinded to the original findings. Iron stains were performed to evaluate for any increased ring sideroblasts. In cases with discrepant degrees of dysplasia (cases n = 13, 11.1%; lineages n = 14, 4.0%), four pathologists (K.M.C., M.X., M.C.P., and J.C.R.) jointly reviewed the aspirates around the microscope for unified results. There was 100% concordance for increased blasts (≥5%) between original pathologists and review pathologist. The cellularity of the bone marrow biopsies was also assessed.
Peripheral blood correlations were performed using sensitivity, specificity, negative predictive values, positive predictive values, positive likelihood ratios, and negative likelihood ratios. To compare specific CBC abnormalities (WBC, ANC, hemoglobin, MCV, and platelet count) between those with and without definitively abnormal ancillary tests, Fisher Exact tests were employed, with Bonferroni correction for five tests, with the corrected significant P value of less than .01. Similar statistics were performed to compare specific CBC abnormalities between those with and without morphologic dysplasia.
Results

Patients and Bone Marrow Cases
A total of 246 patients were identified to have bone marrow evaluations performed for the evaluation of MDS. The male to female ratio was 122:124 (1:1). Of the total 595 bone marrow morphologic studies, the median number of marrows per patient was one, though the number of bone marrows per patient ranged from one to 24. The median age at time of biopsy was 9.3 years. ❚Figure 1❚ demonstrates the percentage of cases by diagnosis, with marrow failure syndromes of FA, DKC, SDS, and Diamond-Blackfan anemia (DBA) representing 27%, chronic/congenital neutropenia 22%, known MDS 2%, known GATA2 mutations 4%, known RUNX1 mutations 2%, aplastic anemia 15%, pancytopenia 7%, bilineage cytopenia 7%, and unilineage cytopenia (anemia, neutropenia, or thrombocytopenia) 8%. In total, 360 (60.5%) cases had concurrent flow cytometry, 586 (98.5%) had concurrent cytogenetics, and 477 (80.2%) had concurrent MDS FISH panels performed. Of all 595 cases, 506 (85.0%) had completely normal bone marrow examinations (dysplasia <10%, normal flow cytometry, normal karyotype, and no MDS FISH panel abnormalities); in total, 194 (78.9%) patients had normal marrow examinations for all marrows performed during the study period.
Bone Marrow Morphology
Of all 595 bone marrow aspirate cases, 543 (91.3%) had relatively normal morphology (<10% dysplastic features), while 52 (8.7%) demonstrated ≥10% dysplasia of at least one lineage and/or increased blasts ≥5%. These 52 cases were from 31 different patients (12.6% of patients) (Supplemental Table 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). A total of 38 (6.4%) cases demonstrated unilineage dysplasia: dyserythropoiesis, n = 6 (1.0%); dysmyelopoiesis, ❚Figure 1❚ Bone marrow cases by clinical prebiopsy diagnosis. Pie chart demonstrating the percentages of cases (n = 595) by diagnosis. The "other" category includes paroxysmal nocturnal hemoglobinuria, polycythemia vera, bone marrow transplant donors, and suspected juvenile myelomonocytic leukemia. MDS, myelodysplastic syndrome; NOS, not otherwise specified; ITP, immune thrombocytopenia purpura.
DOI: 10.1093/ajcp/aqy007 © American Society for Clinical Pathology n = 14 (2.4%); and dysmegakaryopoiesis, n = 18 (3.0%). Bilineage dysplasia was present in 13 cases (2.2%), with four (0.7%) demonstrating erythroid and myeloid dysplasia, eight (1.3%) demonstrating myeloid and megakaryocytic dysplasia, and one (<0.1%) demonstrating erythroid and megakaryocytic dysplasia. Increased blasts (by morphology ≥5%) were identified in seven cases (1.2%), six of which had at least unilineage dysplasia, including one case with megakaryocytic dysplasia, two cases with erythroid and myeloid dysplasia, and three cases with myeloid and megakaryocytic dysplasia. One case only had an increase in blasts with no overt dysplastic features (second abnormal marrow from patient 168). None of the bone marrows had an increase in ring sideroblasts. Of the 52 cases with dysplasia and/or increased blasts, 21 marrows from 13 patients had additional abnormal ancillary tests (40.4%) ❚Table 1❚.
Comparison of Flow Cytometry and Morphology
Of the 360 cases with flow cytometry performed, only 42 (11.7%) had abnormalities, including three (0.9%) with small abnormal B-or T-cell populations of uncertain significance, favored to be reactive (<1% total cells). These three cases were found in one patient each with FA, SDS, and DBA; only one of these three bone marrows had a subsequent bone marrow for evaluation, which did not demonstrate the T-cell clone. A total of 39 cases (10.8%) from 27 patients demonstrated abnormal myeloid progenitors, granulocyte maturation, and/or monocyte maturation by flow cytometry (Supplemental Table 2 ), though only 10 of these cases (2.8%) demonstrated definitive flow cytometric features of a myeloid stem cell neoplasm. These 10 cases all had morphologic dysplasia and/or increased bone marrow blasts. This dysplasia including erythroid dysplasia (n = 1), megakaryocytic dysplasia (n = 2), erythroid and myeloid dysplasia (n = 2), and myeloid and megakaryocytic dysplasia (n = 4); six cases had increased blasts, including one without any dysplasia. Additionally, seven of these 10 cases also demonstrated abnormal cytogenetics. As depicted in Table 1 , these 10 cases were from seven patients who had diagnoses of MDS with excess blasts-1 (MDS-EB-1, patient 30), refractory cytopenia of childhood (patient 65), therapy-related myeloid neoplasm (history of Li Fraumeni syndrome and osteosarcoma with therapy; patient 146), juvenile myelomonocytic leukemia (JMML; second abnormal bone marrow from patient 168), MDS with excess blasts-2 (MDS-EB-2, two marrows from patient 235), and chronic myelomonocytic leukemia with germline GATA2 mutation (three marrows from patient 244). The last remaining case with definitively abnormal flow cytometry was from patient 29 with a history of juvenile dermatomyositis being treated with methotrexate, mycophenolic acid, cyclosporine, prednisolone, and etanercept; this patient's abnormalities were thought to be related to drug effect.
The remaining 29 of 39 abnormal flow cytometry cases were interpreted to have "no definitive abnormal myeloid blasts, monocyte, or myeloid population identified," and "clinical, cytogenetic, and morphologic correlation" was required. In fact, only seven of these flow cytometry reports (five patients) were in cases with morphologic dysplasia, with four cases demonstrating myeloid dysplasia, and one case each with either myeloid and megakaryocytic dysplasia or erythroid and megakaryocytic dysplasia. Four of these five patients were given diagnoses of MDS, unclassifiable (patient 201), MDS with multilineage dysplasia associated with SDS (patient 205), MDS with single lineage dysplasia associated with SDS (patient 230), and suspicious for juvenile myelomonocytic leukemia (patient 246). The last patient had a diagnosis of Brown-Vialetto-Van Laere syndrome, caused by mutations in SLC52A2, which leads to abnormalities in riboflavin. After treatment with high-dose riboflavin this patient's cytopenias normalized, and his bone marrow abnormalities were thought to be due to his underlying disease. Also of note, patient 205 had increased blasts by morphology (8%) most of which were hematogones by flow cytometry.
However, most of these 29 flow cytometry reports noted that the findings were not diagnostic of a myeloid stem cell neoplasm, and many reports favored a reactive/ regenerating marrow. Some of the noted abnormalities of the maturing granulocytes included increased CD14/ CD64 expression (n = 14) and/or abnormal CD13/ CD16 pattern (n = 5), while some of the myeloid progenitor abnormalities included decreased CD13 expression (n = 4), decreased/absent HLA-DR expression (n = 3), increased CD117 (n = 4), and/or CD33 expression (n = 3). Only one case had aberrant monocytes, demonstrating CD56 expression. Some of the cases with abnormal myeloid maturation by flow cytometry were in patients with underlying neutropenia disorders (examples: severe congenital neutropenia, Kostmann-like syndrome), a regenerating marrow, and/or were receiving granulocyte-colony stimulating factor (G-CSF) therapy; the latter two situations in which some abnormalities in myeloid progenitors and granulocytes have been previously reported.
12,13
Comparison of Karyotypes and Morphology
Of the 589 cases with orders for cytogenetics, 586 karyotypes were successfully performed, with only three cases demonstrating lack of metaphase cells, all due to hypocellular marrow aspirates. A total of 523 cases (89.2%) had normal karyotypes. The 63 cases (10.8%) with karyotypic abnormalities included 18 cases (3.1%) with identified constitutional abnormalities such as trisomy 21, and another three cases (0.5%) with a known fragile site. The three karyotypes with a fragile site were detected from a single patient, demonstrating mosaicism for a cell line with 47 chromosomes due to a terminal deletion of 10q with a breakpoint in 10q25, and retention of the deleted segment from 10q25 to 10qter; this cell line was thought to result from spontaneous fragile site expression at 10q25. [15] [16] [17] A total of 42 cases (7.2%), involving 16 patients, had abnormalities that were not constitutional (Table 1) . These cases had abnormalities including del(20q) (n = 14), monosomy 7/del(7q) (n = 12), trisomy 8 (n = 4), both monosomy 7 and trisomy 8 (n = 2), del(5q) (n = 3), and several other abnormalities (n = 7). Of these 42 cases, 26 (61.9%) did not demonstrate dysplasia equal to or greater than 10%, though one did demonstrate an increase in blasts (second abnormal marrow from patient 168). The 16 cases (38.1%) with dysplasia had unilineage dysplasia (dysmyelopoiesis, n = 5; or dysmegakaryopoiesis, n = 5) or bilineage dysplasia (myeloid and megakaryocytic dysplasia, n = 6). Four cases with increased blasts by morphology also had abnormal karyotypes (patients 30, 146, 168 [second abnormal marrow], and 244 [first marrow]). Of note, the 25 cases with abnormal karyotypes and no significant dysplasia or increased blasts were from nine different patients: patient 13 with SDS and low-level monosomy 7, patients 47 and 228 with SDS and low-level i(7q), patients 161 and 163 with SDS and del(20q), patient 21 with DKC and low level monosomy 7, the first abnormal marrow from patient 168 with JMML and multiple abnormal clones, patient 178 with aplastic anemia and trisomy 8, two bone marrows from patient 46 with germline RUNX1 mutation, and two bone marrows from patient 118 with germline GATA2 mutation.
Comparison of MDS FISH Panel and Morphology
Of the 477 cases with MDS FISH panel performed, no abnormalities by FISH were detected in 437 cases (91.6%). A total of 40 (8.4%) had identified abnormalities, with two of these cases demonstrating constitutional abnormalities (mosaic monosomy 7 and constitutional trisomy 8), amounting to 38 cases (8.0%) with identified acquired abnormalities, representing 14 patients (Table 1) . These abnormalities were -7/del(7q) (n = 17), del(20q) (n = 14), del(5q) (n = 2), monosomy 7 and trisomy 8 (n = 2), trisomy 8 (n = 1), i7q (n = 1), and del(5q) and del(7q) (n = 1). Similar to the cases with abnormal karyotypes, 27 cases did not demonstrate morphologic dysplasia equal to or greater than 10%, though one did have an increase in blasts; these cases encompassed nine patients, including four patients with SDS (patients 13, 161, 163, and 228), one with DKC (patient 21), one with JMML (patient 179 first diagnostic marrow), one with aplastic anemia (patient 178), one with germline RUNX1 mutation (two marrows from patient 46), and one with a germline GATA2 mutation (three marrows from patient 118). The remaining 11 cases demonstrated dysplasia, including six with unilineage dysplasia and five with bilineage dysplasia. Four of the cases with abnormal MDS FISH panels had increased blasts by morphology, all of which had -7/del(7q) with or without other FISH abnormalities. The two cases normal by karyotype but abnormal by FISH both depicted monosomy 7 at low levels. Investigating these two cases showed that both had prior concordant abnormal karyotype and MDS FISH panels at bone marrows performed 3 and 5 months previously (patients 21 and 118, respectively). At the current time, FISH identified low levels of monosomy 7 (3% and 3.5%). The concurrent bone marrows demonstrated less than 10% dysplastic features with no increase in blasts. The patient with bone marrow demonstrating 3% monosomy 7 had DKC (patient 21) and did not receive a transplant over the subsequent year, prior to his transfer to an adult hematologist. As such, this abnormal FISH finding was not an impetus for immediate transplantation. The patient with bone marrow demonstrating 3.5% monosomy 7 had a known GATA2 mutation (patient 118) with 11 subsequent bone marrows performed over a period of 5 years (many with low-level karyotypic/FISH abnormalities) prior to moving out of the area without transplantation. Of the six cases with abnormal karyotypes but normal MDS FISH panels, one was from a patient with a RUNX1 mutation and ≥10% megakaryocytic dysplasia by morphology and del(5q) (patient 46). Another case was from a patient who had SDS with isochromosome 7q, not detected by FISH (patient 47); this patient had a study 13 months prior with normal karyotype and MDS FISH panel. The concurrent bone marrow did not demonstrate ≥10% dysplasia. Another case was from a patient with SDS and karyotypic abnormalities of +1, der(1;17)(q10;q10) (patient 230), which would have not been identified by the probes on the MDS FISH panel. The last three cases were from a single patient with a known GATA2 mutation (patient 118) in which FISH did not identify trisomy 8, demonstrated by karyotype to represent 10%, 5%, and 3.3% of metaphase cells. This patient had previous abnormal karyotypes and MDS FISH panels demonstrating trisomy 8 as well as monosomy 7 in various combinations. The three concurrent bone marrow evaluations all had equal to or greater than 10% myeloid dysplasia, and one also had equal to or greater than 10% megakaryocyte dysplasia.
Comparison of Karyotype and MDS FISH Panel
Comparison of Relative Peripheral Blood Values and Ancillary Tests
The presence of abnormal ancillary tests (definitive flow cytometry findings, abnormal acquired karyotypic abnormalities, and abnormal MDS FISH panel results) was compared to peripheral blood values including the WBC count, platelet count, hemoglobin, MCV, and ANC ❚Table 3❚. No correlations were present between decreased WBC count (corrected P value .94), decreased hemoglobin (corrected P value .70), increased MCV (corrected P value .34), or decreased ANC (corrected P value 1.00) with the presence of abnormal ancillary tests. However, the cases with abnormal marrow ancillary tests had an increased rate of thrombocytopenia (P < .001 with Bonferroni correction). Of the 51 cases with abnormal ancillary tests and platelet values, only two cases did not have thrombocytopenia, both from a single patient who had a known GATA2 mutation with no known transfusions (patient 118). Of the 511 cases with normal ancillary tests and known platelet values, 311 were found to be thrombocytopenic. Hence, the absence of thrombocytopenia predicted normal ancillary tests (negative predictive value = 99.0%; sensitivity = 96.1%; Similar statistics were performed on WBC counts, platelet counts, hemoglobins, MCVs, and ANCs between cases with morphologic dysplasia and those without morphologic dysplasia. Again the absence of thrombocytopenia predicted the absence of any dysplastic lineage (corrected P value <.001; negative predictive value, 96.53%).
Only four of the 246 patients demonstrated blasts in the peripheral blood, all of whom eventually received a diagnosis of a myeloid neoplasm. Patient 168 had 1%, 1%, and 10% peripheral blood blasts at the time of his three bone marrow evaluations, the last two evaluations consistent with a diagnosis of juvenile myelomonocytic leukemia. Similarly, patient 246 had 4% peripheral blood blasts at the time of his marrow which was suspicious for JMML. Patient 235 had 4% and 2% peripheral blood blasts at the time of her two bone marrows, with a diagnosis of MDS-EB-2. Lastly, patient 244 with a germline GATA2 mutation had peripheral blood blasts enumerated at 4%, 5%, and 3% at the time of his three bone marrows, all with a diagnosis of CMML-1. There were no patients with peripheral blood blasts that did not have increased blasts in the bone marrow. 
Discussion
In this study, flow cytometry detected at least mild antigenic abnormalities in 39 cases (10.8%), only 10 of which were definitive diagnostic abnormalities. These 10 latter bone marrows all had morphologic dysplasia 10% or greater and/or increased blasts by morphology, and seven of the 10 had abnormal cytogenetics. As such, flow cytometry was mainly useful in the characterization of the blast population, immunophenotypically identified to be myeloid blasts. However, flow cytometry was also found to be mildly abnormal in 29 cases, of which six did have MDS or JMML. Flow cytometry may be useful in the evaluation of MDS in situations in which there is borderline dysplasia to help support the diagnosis of MDS. Additionally, in cases with morphologic dysplasia, flow may be normal, suggesting that there is another cause of the dysplasia other than MDS.
Of note, MDS detection by flow cytometry in pediatrics has previously been reported to be not as useful as in adults. Aalbers et al 18 found that the scoring system developed by Ogata et al 19 was not as useful in diagnosing refractory cytopenia of childhood as it was in adult low-grade MDS. Children may have fewer abnormalities, with fewer differences from normal controls. Reports of patients with nonclonal cytopenias often identified a single myeloid immunophenotypic abnormality in 5% to 42% of patients. [20] [21] [22] [23] [24] Along this same line, flow cytometry performed on regenerative marrows and/or G-CSF-treated marrows have been identified to have abnormalities in myeloid blasts, maturing granulocytes, and monocytes, including increased expression of CD14 and CD64 on maturing granulocytes, dyssynchronous CD13 and CD16 expression on maturing granulocytes, and CD56 expression on monocytes 12, 13 ; these abnormalities were identified in some of our cases in the setting of G-CSF therapy (Supplemental Table 2 ).
In this study, karyotype demonstrated acquired abnormalities in 42 cases, 26 of which did not have dysplasia equal to or greater than 10% by morphology. The MDS FISH panel detected nonconstitutional abnormalities in 38 cases, 36 of which also had an abnormal concurrent karyotype. The two cases missed by karyotype had low-level monosomy 7 ranging from 3% to 3.5%. Both of these patients had prior abnormal karyotypes and MDS FISH panels, and one of the patients had a known GATA2 mutation. As such, FISH may be helpful in identifying low-level clones, especially in patients with GATA2 mutations, though these cases in our study did not prompt immediate transplantation or a change in management.
Based on these findings, in comparison to our prior ordering system in which morphology, flow cytometry, karyotypes, and MDS FISH panel were all ordered as required, our hospital has altered our ordering algorithm ❚Figure 2❚ to require bone marrow aspirates and core biopsies for morphology and cytogenetics for karyotyping, but to order flow cytometry and the MDS FISH panel as "if indicated after pathologist review." The pathologist will send flow cytometry if (1) blasts are increased to better characterize blasts, (2) dysplasia is present, and/ or (3) there is clinical suspicion of disease evolution; in these instances flow cytometry can help further define the MDS diagnosis or help rule out a MDS diagnosis. The pathologist can order the MDS FISH panel if there is a prior abnormal karyotype or relevant FISH result, or if the patient has a known GATA2 mutation. Cytogeneticists may request FISH to help clarify any karyotypic abnormalities or if a full 20 metaphase cells cannot be analyzed. However, as stated above, even in the cases that did not have a full 20 metaphase cells to evaluate, FISH did not add any further information. The lack of a need for a concurrent MDS FISH panel has been supported by previous reports of large series of patients, predominantly in adults, demonstrating a high concordance between karyotypes and FISH studies. [25] [26] [27] [28] [29] [30] [31] FISH has been found to be useful when a full 20 metaphase cells cannot be analyzed and/ or to help clarify any karyotypic findings. 25, 26, 28, 30, 32 The finding of two cases with abnormal FISH findings in the setting of normal karyotypes supports that FISH can detect low-level clones, as previously reported. 32 These two cases both had monosomy 7, detected at 3% and 3.5%, above the positive cut-off range for the FISH assays at our institution. Of note, chromosome 7 abnormalities, including monosomy 7, are the most common cytogenetic abnormalities detected in childhood MDS, followed by abnormalities of chromosomes 8 and 5 (most commonly trisomy 8 and del(5q), respectively). 5, 7, [32] [33] [34] [35] In this study, many patients were identified to have at least unilineage dysplasia without identified abnormal clones by flow cytometry or cytogenetics. A number of these patients had pancytopenia with dysplasia but were found to have other etiologies for their cytopenias than MDS, including viral suppression (viruses included HHV6 and influenza A) and vitamin B 12 deficiency (Supplemental Table 1 ). In addition, one patient with juvenile dermatomyositis on multiple drugs, including methotrexate, mycophenolic acid, cyclosporine, prednisolone, and etanercept, was found to have erythroid dysplasia (patient 29). The lack of an abnormal karyotype and/or abnormal flow cytometry (for myeloid dysplasia) in these patients suggests caution in the interpretation of dysplasia without a good clinical history and thorough examination. Dysplasia has been previously reported in children due to viruses, nutritional deficiencies, and autoimmune disorders. [36] [37] [38] [39] [40] Additionally, dysplasia over 10% has been identified in healthy control populations. 41 Of the 246 patients in this study, only 20 (8.1%) had identifiable definitive flow cytometry, karyotypic, and/or FISH abnormalities (Table 1 ). These 20 patients had a total of 51 abnormal bone marrow examinations ❚Figure 3❚. Of these 20 patients, five demonstrated only an abnormal karyotype/MDS FISH panel and otherwise did not meet the criteria for a MDS diagnosis (including patients 47 and 228 with i(7)(q10), patients 161 and 163 with del(20q), patient 178 with trisomy 8). An additional patient was thought to have dysplasia due to her medications (patient 29). However, the remaining 14 patients included not only the more traditional MDS classifications such as MDS-EB-2, refractory cytopenia of childhood, therapy-related myeloid neoplasm, and JMML but also three with myeloid neoplasms with germline mutations (RUNX1 or GATA2) (MDS with single lineage dysplasia, MDS with isolated del(5q), and CMML-1) and five with myeloid neoplasms associated with bone marrow failure syndromes SDS, DKC, and severe congenital neutropenia (MDS with single lineage dysplasia, MDS with multilineage dysplasia, MDS-EB-1, and MDS, unclassifiable). These latter cases are new classifications by the WHO 2016 revision, 10 and it is in these patients and their families that surveillance marrows should be performed. Yearly bone marrows with cytogenetics have been recommended for patients with germline predisposition syndromes (including mutations in RUNX1 and GATA2 genes, and the syndromes FA, SDS, DKC, and severe congenital neutropenia). [42] [43] [44] [45] [46] This screening can help detect the emergence of dysplasia and/or an abnormal clonal population. 42, 44 Early detection is important, as outcomes status post hematopoietic stem cell transplant are improved for those with early MDS compared to those with advanced MDS and/or acute leukemia. 42, [47] [48] [49] [50] An interesting finding in this study is the association of normal platelet count (ie, lack of thrombocytopenia) with the lack of bone marrow abnormalities (morphologic dysplasia and/or definitively abnormal ancillary tests). This result leads to the suggestion that one may not need to perform bone marrow evaluations if the platelet count is normal. While this suggestion may seem somewhat extreme, we note that all but one of the patients (two cases) with abnormal ancillary tests had thrombocytopenia (alone or in combination with other cytopenias). Performing additional groupings (low platelets plus low hemoglobin, etc) did not further help identify any specific laboratory value combinations that were always associated with abnormal ancillary tests (data not shown), as many of the cases with no bone marrow abnormalities demonstrated macrocytic anemia, thrombocytopenia, and/or neutropenia in various combinations. Additionally, we were unable to qualify the degree of thrombocytopenia (such as severe vs mild thrombocytopenia) to help further DOI: 10.1093/ajcp/aqy007 © American Society for Clinical Pathology refine the recommendations for bone marrow examinations due to the different reference ranges of CBC values in pediatrics and the inability to account for transfusions and drug effects, such as G-CSF. Such findings open the door to seeking surveillance testing that avoids periodic, costly marrow examinations.
Using the knowledge that all but one patient with abnormal ancillary tests had thrombocytopenia, one may be able to limit the number of screening bone marrows performed in the MDS surveillance for patients with IBMFS. One may also logically perform bone marrow surveillance at the time of inherited syndrome diagnosis for a baseline and subsequently only when there is a change in the CBC laboratory values. For example, of the five patients who developed MDS and/or abnormal cytogenetics after their initial bone marrows in this study, the two patients who did develop MDS (patient 21 with DKC and patient 46 with germline RUNX1 mutation) both demonstrated decreases in their hemoglobin values from normal per age to decreased per age (though notably subtle changes, Table 1 ). The three other individuals only developed abnormal clonal cytogenetics that were not diagnostic of MDS (patients 47 and 161 with SDS and patient 178 with aplastic anemia). These abnormalities developed 7.3 years after diagnosis for the case of DKC with MDS, 2.9 and 4.6 years after diagnosis for the cases of SDS, and 6 years after the diagnosis of aplastic anemia. Eleven of the other patients had MDS diagnosed on their first bone marrow evaluation at our institution. By using a more thoughtful approach, one can decrease the number of marrow examinations on these patients.
In these IBMFS and syndromes with germline mutations, pathologists must be aware of underlying dysplasia due to the inherited mutation and not necessarily due to an evolving MDS. For example, patient 46 with a germline RUNX1 mutation had megakaryocytic "dysplasia" at the time of diagnosis and the time of abnormal clone development; megakaryocytic abnormalities have been found at baseline in individuals with RUNX1germline mutations even prior to the development of MDS or AML (Chisholm et al, unpublished data). Patient 113 (Supplemental Table 1 © American Society for Clinical Pathology megakaryocytic dysplasia in three bone marrows without development of an abnormal clone by flow cytometry or karyotype. Similarly, the bone marrow from a patient with thrombocytopenia absent radii syndrome also had baseline dysmegakaryopoiesis. This phenomenon of dysplasia in lineages prior to the development of karyotypic abnormalities has also been identified in individuals with germline GATA2 mutations. 51 However, in our study, the three patients with known GATA2 mutations either presented with MDS (patient 118 with MDS with single lineage dysplasia and patient 244 with CMML-1) or did not have any dysplasia or abnormal ancillary tests (patient 72).
While one of the strengths of our study is the number of patients and cases analyzed, our study does have several limitations. Our hospital is a referral hospital for IBMFS for hematologic malignancy screening and transplantations, which may have led to an increase in MDS cases or in patients with MDS identified in their first bone marrow at our hospital. The limited number of patients who demonstrated normal initial bone marrow evaluations but who evolved into MDS, hampers our ability to make stronger conclusions regarding which changes in CBC values are more suggestive of disease evolution. Additionally, multiple pathologists were involved in the original review of the bone marrows in this study, spanning 16 years. Rereview by a single hematopathologist identified a dysplasia discordance rate of 11.1% of cases (4.0% of lineages); these cases were reviewed by four pathologists around the microscope for agreement of percentage of dysplasia. These discrepancies were predominantly at the boundaries of the definition of dysplasia (10%) and due to lack of uniformity in the use of subjective qualifiers vs percentages; poor interobserver concordance in this range of morphologic dysplasia has been previously reported. 41 As such, we would suggest erring on the safe side in ordering ancillary tests such as flow cytometry, in that if there is dysplasia close to 10%, sending for the ancillary tests is advisable.
Our proposed ordering algorithm also has some limitations. Firstly, to make this more minimal system work, pathologists need to be screening the marrows soon after receipt to determine if flow cytometry should be added for an increased blast percentage or dysplasia. The evaluation of blasts in pediatric cases can be hampered by increased early hematogones, and, in cases of uncertainty, we recommend sending the flow cytometry. As an example, patient 205 with SDS was found to have up to 8% morphologic blasts in the bone marrow aspirate. On flow cytometry, only 3.6% myeloid blasts were identified with an increased percentage of hematogones (estimated at 25% by flow cytometry). Secondly, the cytogenetics lab must be able to obtain at least 20 metaphase cells for analysis, otherwise an MDS FISH panel will have to be employed. At this time, next-generation sequencing panels are not in our algorithm and are more in use once MDS has been definitively diagnosed. These panels may include SF3B1 in order to appropriately triage the number of ring sideroblasts for an accurate diagnosis. At our hospital, often DNA from bone marrow aspirates is banked for future potential use in molecular assays. As new modalities emerge for evaluation for MDS, some may be determined to outperform others; these tests will need to be under constant observation to see if they are effective in the diagnosis and/or treatment of the patient.
One worry about eliminating the concurrent MDS FISH panel from some patients is the decreased sensitivity of chromosome analysis to identify cryptic or small deletions. In particular, some chromosomal changes in FA are better identified by FISH assays. As such, we have developed a FISH panel specifically for FA patients, encompassing the cytogenetic changes most commonly found in this population, including some which have prognostic information; these changes are gain of 1q, gain of distal 3q, monosomy 7/del(7q), and loss of 11q. [52] [53] [54] [55] [56] It is also interesting to note that some cases with normal FISH results had abnormal karyotypes, either because the chromosome abnormalities could not be detected by the FISH probes in the panel, or because of a real discrepancy. Discrepant results in which abnormalities are detected by G-banded chromosome analysis but not by interphase FISH can be due to enrichment of dividing cells with the chromosomal abnormality, or analysis of different cultures for karyotype and FISH.
In this era where some believe that "more is better," this series demonstrates that the combination of morphologic evaluation and karyotype without flow cytometry and/or MDS FISH is sufficient to detect the abnormalities within this series of surveillance bone marrows. This system is also more cost effective. Flow cytometry can be employed more resourcefully. In addition, a more tailored FISH assay may be useful in such cases as FA. These findings would reduce unnecessary testing without decreasing the sensitivity of detecting myelodysplasia. Additionally, taking into account stable vs decreasing CBC values (particularly platelets) may lead to less bone marrow evaluations. In conclusion, we suggest caution in going forward with bone marrow evaluations and ancillary testing-more is not always better.
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